Browsing by Subject "PLUS RIBAVIRIN"

Sort by: Order: Results:

Now showing items 1-3 of 3
  • Rembeck, Karolina; Alsio, Asa; Christensen, Peer Brehm; Färkkilä, Martti Antero; Langeland, Nina; Buhl, Mads Rauning; Pedersen, Court; Morch, Kristine; Westin, Johan; Lindh, Magnus; Hellstrand, Kristoffer; Norkrans, Gunnar; Lagging, Martin (2012)
  • Alsio, Asa; Rembeck, Karolina; Askarieh, Galia; Christensen, Peer Brehm; Färkkilä, Martti Antero; Langeland, Nina; Buhl, Mads Rauning; Pedersen, Court; Morch, Kristine; Haagmans, Bart L.; Nasic, Salmir; Westin, Johan; Hellstrand, Kristoffer; Norkrans, Gunnar; Lagging, Martin (2012)
  • SUCCESS Study Investigators; Färkkilä, Martti (2010)
    The benefit of extending treatment duration with peginterferon (PEG-IFN) and ribavirin (RI3V) from 48 weeks to 72 weeks for patients with chronic hepatitis C genotype 1 infection has not been well established. In this prospective, international, open-label, randomized, multicenter study, 1,428 treatment-nave patients from 133 centers were treated with PEG-IFN alfa-26 (1.5 mu g/kg/week) plus RBV (800-1,400 mg/day). Patients with detectable hepatii is C virus (HCV) RNA and a >= 2-logio drop in IICV RNA levels at week 12 (slow responders) were randomized 1:1 to receive 48 weeks (n = 86) or 72 weeks (n = 73) of treatment. Sustained virologic response (SVR) rates were 43% in slow responders treated for 48 weeks and 48% in slow responders treated for 72 weeks (P = 0.644). Relapse rates were similar in slow responders treated for 48 or 72 weeks (47% versus 33%, P = 0.169). The safety profile was similar in both treatment arms; serious adverse events leading to discontinuation of treatment were observed in 3.5% of slow responders treated for 48 weeks and 8.2% of those treated for 72 weeks. Among slow responders with a